SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/20/20 EyePoint Pharmaceuticals, Inc. 8-K:8,9 2/20/20 2:15M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 24K 2: EX-99.1 Miscellaneous Exhibit HTML 34K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 20, 2020
EyePoint Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
|
26-2774444 |
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
480 Pleasant Street
(Address of Principal Executive Offices, and Zip Code)
(617) 926-5000
Registrant’s Telephone Number, Including Area Code
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.001 |
|
EYPT |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On February 20, 2020, EyePoint Pharmaceuticals, Inc. posted an updated corporate presentation on its website at www.eyepointpharma.com. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Corporate Presentation, dated February 20, 2020
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
EYEPOINT PHARMACEUTICALS, INC. |
|
|
|
||
Date: February 20, 2020 |
|
|
|
/s/ Nancy Lurker |
|
|
|
|
|
|
|
|
|
President and Chief Executive Officer |
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on / For Period end: | 2/20/20 | None on these Dates | ||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/12/21 EyePoint Pharmaceuticals, Inc. S-3 3:260K Donnelley … Solutions/FA 2/02/21 EyePoint Pharmaceuticals, Inc. 424B5 1:493K Donnelley … Solutions/FA 2/01/21 EyePoint Pharmaceuticals, Inc. 424B5 1:496K Donnelley … Solutions/FA 1/15/21 EyePoint Pharmaceuticals, Inc. S-3 4:662K Donnelley … Solutions/FA 11/06/20 EyePoint Pharmaceuticals, Inc. S-8 11/06/20 3:88K Donnelley … Solutions/FA 8/05/20 EyePoint Pharmaceuticals, Inc. 424B5 1:536K Donnelley … Solutions/FA |